Wells Fargo & Company MN Has $396,000 Position in Neos Therapeutics, Inc. (NEOS)
Wells Fargo & Company MN lifted its position in Neos Therapeutics, Inc. (NASDAQ:NEOS) by 13.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,253 shares of the company’s stock after acquiring an additional 6,223 shares during the period. Wells Fargo & Company MN owned approximately 0.24% of Neos Therapeutics worth $396,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the stock. State of Wisconsin Investment Board bought a new stake in Neos Therapeutics during the 2nd quarter worth approximately $102,000. OMERS ADMINISTRATION Corp bought a new stake in Neos Therapeutics during the 2nd quarter worth approximately $110,000. Rhumbline Advisers increased its stake in Neos Therapeutics by 13.6% during the 2nd quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock worth $149,000 after purchasing an additional 2,441 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in Neos Therapeutics by 103.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 43,700 shares of the company’s stock worth $320,000 after purchasing an additional 22,200 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Neos Therapeutics by 37.1% during the 1st quarter. Bank of New York Mellon Corp now owns 59,841 shares of the company’s stock worth $431,000 after purchasing an additional 16,191 shares in the last quarter. Institutional investors and hedge funds own 44.66% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Wells Fargo & Company MN Has $396,000 Position in Neos Therapeutics, Inc. (NEOS)” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://theolympiareport.com/2017/11/15/wells-fargo-company-mn-has-396000-position-in-neos-therapeutics-inc-neos.html.
NEOS has been the subject of a number of research reports. Zacks Investment Research cut Neos Therapeutics from a “buy” rating to a “sell” rating in a research note on Thursday, October 19th. Cantor Fitzgerald reissued a “buy” rating and set a $20.00 target price on shares of Neos Therapeutics in a research note on Tuesday, September 26th. Cowen and Company reissued a “buy” rating on shares of Neos Therapeutics in a research note on Thursday, October 26th. Wells Fargo & Company set a $14.00 target price on Neos Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, October 18th. Finally, ValuEngine raised Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 12th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. Neos Therapeutics has a consensus rating of “Buy” and a consensus target price of $14.00.
Neos Therapeutics, Inc. (NASDAQ:NEOS) opened at $10.95 on Wednesday. Neos Therapeutics, Inc. has a 52 week low of $4.85 and a 52 week high of $13.15. The company has a current ratio of 2.42, a quick ratio of 2.84 and a debt-to-equity ratio of 4.01.
Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.22. The company had revenue of $6.70 million during the quarter. Neos Therapeutics had a negative net margin of 339.52% and a negative return on equity of 551.26%. research analysts expect that Neos Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.